An evaluation of the impact of the pneumococcal conjugate vaccine (PCV10) programme on invasive pneumococcal disease in Nigeria by using serial carriage studies and mathematical modelling

Principal Investigator: Ifedayo Adetifa
Institution: KEMRI Wellcome Trust Research Programme, Kilifi, Kenya (KWTRP; London School of Hygiene and Tropical Medicine (LSHTM)
Co-Investigators: Anthony Scott, John Ojal, Kofo Odeyemi, Victor Inem, Christy Okoromah, Aishatu Adamu, Musa Bello, Isa Abubakar

Start date: July 2018

The World Health Organization (WHO) currently recommends that all countries introduce PCVs containing 10 (PCV10) or 13 (PCV13) serotypes in their immunisation programmes especially those with significant mortality in children aged <5 years.1 The first PCV, containing seven serotypes (PCV7), was licensed and introduced in the USA in 2000 and other developed countries followed suit.2 From 2009, PCV7 was replaced with formulations containing more serotypes – PCV10 and PCV13- in high income countries, because of an increase in IPD due to non-vaccine type (VT) pneumococci. This phenomenon also known as serotype replacement disease (SRD) was of such magnitude that it reduced the gains seen following PCV7 introduction.

Aim and Impact

To evaluate impact of the PCV10 on IPD in Nigeria using mathematical modelling approaches based on sequential cross-sectional carriage data, generating data to support future vaccination programmes.